Analyst Reports

LFST LFST

2026-08-20

SAMPLE — 1 week old

This is a sample report. Unlock Premium to see the latest reports and the full library.

Executive summary

LifeStance Health has undergone a clear turnaround: revenues grew 13.9% in FY2025 and accelerated to +26.1% in Q2 2026, while the company moved from a net loss in FY2024 to a net profit of $9.66M in FY2025 and a record $23.61M in Q2 2026. The balance sheet is healthy, with cash covering 87.2% of long-term debt and a debt-to-equity ratio of only 17.5%.

Verdict

Sobrevalorada

Stock evolution (2y)

The stock rose from $5.72 in August 2024 to $12.83 in August 2026, a total return of +124.3%. In the last year alone, it gained +139.8%, with a minimum of $3.79 and a maximum of $12.83. The recent jump was driven by a strong profitable quarter, positive guidance and a newly announced buyback program.

Future catalysts

▸Continuación de la expansión de márgenes operativos y netos
▸Elevación de guía anual por la aceleración de ingresos
▸Programa de recompra de acciones puede sostener el precio

Key risks

▸La rentabilidad actual es baja (margen neto 5.4%) y el múltiplo implícito puede ser exigente
▸Venta de acciones por parte de un director en agosto 2026 sugiere toma de beneficios
▸Riesgo de ejecución ante la rápida expansión y posible desaceleración del crecimiento

Key financial drivers

The re-rating reflects a fundamental improvement: revenue growth accelerated from 13.9% in FY2025 to 26.1% in Q2 2026, operating income turned positive and net margins reached 5.4% in Q2 2026. Debt reduction and a stable share count (382M shares in Q2 2026) also supported investor confidence.

Informational only: This report is descriptive analysis of public SEC data (Form 4 filings, financial statements) and public market data. It is general, non-personalised information — NOT investment advice within the meaning of Spanish Law 6/2023 nor an investment recommendation under Regulation (EU) 596/2014 (MAR). It does not consider your financial situation, objectives or risk profile. Historical performance does not guarantee future results. Verify data against primary sources and make your own decisions or consult a registered adviser.

Want a free daily digest of insider activity? Subscribe below: